Breaking News

AbCellera, Lilly Partner to Develop Antibodies Against COVID-19

Will leverage AbCellera's rapid pandemic response platform and Lilly's global development, manufacturing and distribution capabilities

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbCellera and Eli Lilly and Co. entered an agreement to co-develop antibody products for the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The collaboration will leverage AbCellera’s rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly’s global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies.   Within one week of receiving a blood...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters